Abstract
Researchers at the University of Central Florida and the University of the Witwatersrand, Johannesburg have identified gold (III) compounds that demonstrate antimicrobial activity against Mycobacterium tuberculosis (Mtb) and Mycobacterium abscessus (Mab). The identified compounds could potentially be used to treat infections such as tuberculosis (TB), TB-like pulmonary infections, and soft-tissue and wound infections. The compounds may also be effective against drug-resistant strains of mycobacteria.
Partnering Opportunity
The research team is looking for partners to further develop the technology for commercialization.
Stage of Development
Preclinical
Benefit
Enables the development of noncytotoxic drugs that are active against both Mtb and Mab (and other non-tuberculosis mycobacterial pathogens)Can be used to develop novel drugs that target bacterial topoisomerasesMarket Application
Treatment of tuberculosisPublications
Evidence for Inhibition of Topoisomerase 1A by Gold(III) Macrocycles and Chelates Targeting Mycobacterium tuberculosis and Mycobacterium abscessus, Antimicrobial Agents and Chemotherapy, 2018 Apr 26;62(5). pii: e01696-17. doi: 10.1128/AAC.01696-17.
Brochure
